Cargando…

Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis

A meta-analysis has systematically investigated the antineoplastic efficacy and safety of somatostatin analogs (SSAs) in advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). Randomized controlled trials (RCTs) reporting the hazard ratio (HR) for disease progression (DP) were evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merola, Elettra, Panzuto, Francesco, Fave, Gianfranco Delle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542298/ https://www.ncbi.nlm.nih.gov/pubmed/28402955 http://dx.doi.org/10.18632/oncotarget.16686

Ejemplares similares

The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
por: Panzuto, Francesco, et al.
Publicado: (2022)

Utility of histopathological revision in the management of gastro-entero-pancreatic neuroendocrine neoplasia
por: Marasco, Matteo, et al.
Publicado: (2023)

Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias
por: Albers, Max B., et al.
Publicado: (2020)

Role of [(18)F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors
por: Magi, Ludovica, et al.
Publicado: (2022)

Tumor mutation burden in gastro-entero-pancreatic-neuroendocrine neoplasms
por: Jeong, Sun Young, et al.
Publicado: (2023)

Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma
por: Ooki, Akira, et al.
Publicado: (2023)

Diagnosis, Management and Theragnostic Approach of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms
por: Piscopo, Leandra, et al.
Publicado: (2023)

Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms
por: Panzuto, Francesco, et al.
Publicado: (2017)

Endoscopic techniques for diagnosis and treatment of gastro-entero-pancreatic neuroendocrine neoplasms: Where we are
por: Rossi, Roberta Elisa, et al.
Publicado: (2022)

Microenvironment and tumor inflammatory features improve prognostic prediction in gastro‐entero‐pancreatic neuroendocrine neoplasms
por: Milione, Massimo, et al.
Publicado: (2019)

The effect of alcohol on gastro-entero-pancreatic hormones.
por: Henry, R. W., et al.
Publicado: (1981)

Screening for malnutrition in patients with gastro-entero-pancreatic neuroendocrine tumours: a cross-sectional study
por: Qureshi, Sheharyar A, et al.
Publicado: (2016)

An 11-year retrospective study: clinicopathological and survival analysis of gastro-entero-pancreatic neuroendocrine neoplasm
por: Liu, Hua, et al.
Publicado: (2020)

Antiproliferative effects of somatostatin analogs in endocrine tumours
por: Zatelli, Maria Chiara
Publicado: (2009)

Visceral Obesity Is Associated with Shorter Progression-Free Survival in Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Neoplasia
por: Santos, Ana P., et al.
Publicado: (2022)

The Glasgow Prognostic Score Predicts Survival Outcomes in Neuroendocrine Neoplasms of the Gastro–Entero–Pancreatic (GEP-NEN) System
por: Gebauer, Niklas, et al.
Publicado: (2022)

Gastro-Entero-Colitis of Infancy and Childhood
por: Christian, G. W.
Publicado: (1892)

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Kwekkeboom, D. J., et al.
Publicado: (2003)

Glyoxalase 1 copy number variation in patients with well differentiated gastro-entero-pancreatic neuroendocrine tumours (GEP-NET)
por: Xue, Mingzhan, et al.
Publicado: (2017)

Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study
por: Masui, Toshihiko, et al.
Publicado: (2020)

Radiological Imaging of Gastro-Entero-Pancreatic Neuroendocrine Tumors. The Review of Current Literature Emphasizing the Diagnostic Value of Chosen Imaging Methods
por: Półtorak-Szymczak, Gabriela, et al.
Publicado: (2021)

Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET)
por: Lamberti, Giuseppe, et al.
Publicado: (2023)

Disseminated Well-Differentiated Gastro-Entero-Pancreatic Tumors Are Associated with Metabolic Syndrome
por: Santos, Ana P., et al.
Publicado: (2019)

Resection of the primary tumor improves survival in patients with gastro‐entero‐pancreatic neuroendocrine neoplasms with liver metastases: A SEER‐based analysis
por: Zheng, Mengzhen, et al.
Publicado: (2019)

MicroRNAs regulatory networks governing the epigenetic landscape of MEN1 gastro‐entero‐pancreatic neuroendocrine tumor: A case report
por: Luzi, Ettore, et al.
Publicado: (2021)

Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice
por: Rust, Edmond, et al.
Publicado: (2012)

Synchronous AML and pancreatic neuroendocrine neoplasm, both successfully treated with somatostatin analogs and decitabine
por: Ehsanullah, Syed, et al.
Publicado: (2022)

Treatment of Advanced Gastro-Entero-Pancreatic Neuro-Endocrine Tumors: A Systematic Review and Network Meta-Analysis of Phase III Randomized Controlled Trials
por: Ricci, Claudio, et al.
Publicado: (2021)

Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
por: Machado-Alba, J. E., et al.
Publicado: (2022)

Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice.
por: Weckbecker, G., et al.
Publicado: (1997)

Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs
por: Fernandes, Isabel, et al.
Publicado: (2012)

Observational Study on Antibody Response to COVID-19 Vaccines in PAtients with Gastro-Entero-PanCreatic Cancers and NeuroendocrIne NeoplAsms on Systemic TreatmEnts (VACCINATE)
por: Laffi, Alice, et al.
Publicado: (2023)

Effects of somatostatin analogs on uptake of radiolabeled somatostatin analogs on imaging: a systematic review and meta-analysis
por: Wang, Rang, et al.
Publicado: (2023)

Aberrant Expression of Long Non Coding RNA HOTAIR and De-Regulation of the Paralogous 13 HOX Genes Are Strongly Associated with Aggressive Behavior of Gastro-Entero-Pancreatic Neuroendocrine Tumors
por: Di Mauro, Annabella, et al.
Publicado: (2021)

Management of Functional Pancreatic Neuroendocrine Neoplasms
por: Magi, Ludovica, et al.
Publicado: (2023)

Novel Molecular Targets for the Treatment of Gastroenteropancreatic Endocrine Tumors: Answers and Unsolved Problems
por: Capurso, Gabriele, et al.
Publicado: (2012)

Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives
por: Baldelli, Roberto, et al.
Publicado: (2014)

Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
por: Darden, Christina, et al.
Publicado: (2021)

THU511 Somatostatin Analogs Or Active Surveillance In Sporadic And MEN1 Associated Non-functioning Pancreatic Neuroendocrine Tumors
por: Raia, Salvatore, et al.
Publicado: (2023)

Somatostatin Analogs Treated Small Intestinal Neuroendocrine Tumor Patients Circulating MicroRNAs
por: Li, Su-Chen, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_q9a9s412vn11ceibpgg376l8l2